Compare FedEx Corporation (FDX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs GSK plc — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and GSK plc for 93 Days on average.
| FDX | GSK | |
|---|---|---|
Market Cap | $69.04B | $91.88B |
Volume | 1,287,367 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $339.35 | $61.18 |
52-Week Low | $180.87 | $43.24 |
Typical Hold Time | 87 Days | 93 Days |
Enterprise Value | $98.68B | $111.88B |
Dividend Yield | 1.67% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FDX trades at $290.98, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $6.31 exceeding the $5.96 estimate. Revenue for 2025 was $87.93 billion, with a net income margin of 4.68%. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and geopolitical tensions pose near-term risks. Earnings growth and cost-cutting initiatives support upside, while margin pressure from higher diesel prices and competitive pressures are key concerns for investors.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
